Core Viewpoint - Avalon GloboCare Corp. has acquired RPM Interactive, Inc., a generative AI publishing and software company, and is focusing on the development and commercialization of the Catch-Up platform, a SaaS solution for automated video generation [1][2]. Group 1: Acquisition and Leadership - Michael Mathews, CEO of RPM and a board member of Avalon, discussed the acquisition and its implications during an interview [1]. - The acquisition of RPM is part of Avalon's strategy to enhance its product offerings in the precision diagnostic consumer products sector [1]. Group 2: Catch-Up Platform Development - The Catch-Up platform is designed to automatically generate recap-style videos using generative AI applications and large language models [2]. - This platform will be marketed to content creators, media companies, and brands, allowing them to produce videos without manual editing or technical expertise [3]. Group 3: Marketing and Product Integration - Avalon plans to utilize the Catch-Up platform to support marketing initiatives for its KetoAir™ breathalyzer, which is FDA-registered and aimed at helping consumers manage their wellness [4]. - The integration of the Catch-Up platform is expected to enhance the volume of video content produced by content creators, thereby increasing engagement and visibility [3].

FREEHOLD, N.J., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of precision diagnostic consumer products, today announced that Michael Mathews, a member of the Company’s Board of Directors and Chief Executive Officer of RPM Interactive, Inc. (“RPM”), participated in an interview with Proactiveinvestors.com. Recently, the Company announced that it has acquired RPM Interactive, Inc. (“RPM”), a generative artificial intelligence (“AI”) publishin ...

NEW YORK, Dec. 23, 2025 (GLOBE NEWSWIRE) -- E.F. Hutton & Co., a leading investment bank providing strategic advisory and capital markets services, today is proud to have served as exclusive financial advisor to RPM Interactive, Inc. (“RPM”) in its acquisition by Avalon GloboCare Corp. (NASDAQ: ALBT). The transaction, completed as an all-stock merger, represents a significant strategic milestone for RPM and underscores E.F. Hutton’s continued leadership in advising innovative, high-growth companies across t ...

Company forms a new subsidiary, Avalon Quantum AI, LLC, in connection with the acquisition Acquisition expected to resolve Nasdaq minimum stockholders’ equity deficiency RPM Interactive has developed a fully automated, generative AI powered SaaS platform for creating short-form video content FREEHOLD, N.J., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of precision diagnostic consumer products, today announced that it has acquired RPM Inter ...

Core Viewpoint - Avalon GloboCare Corp. has acquired RPM Interactive, Inc. to enhance its digital marketing capabilities and strengthen its balance sheet through an all-stock transaction valued at $19.5 million [1][2]. Transaction Structure - RPM merged into Avalon Quantum AI, LLC, a newly formed wholly owned subsidiary, with Avalon issuing 19,500 Series E non-voting convertible preferred shares [2]. - The preferred shares can be converted into common stock at $1.50 per share after May 12, 2026, pending shareholder approval [2]. Technology and Product Integration - RPM's "Catch-Up" SaaS platform automates the creation and distribution of short-form videos, allowing Avalon to produce branded content efficiently [3]. - The platform sources clips, generates AI narration and avatars, and publishes content across major platforms, with commercialization expected early next year [3]. Strategic Rationale - Avalon intends to utilize the AI platform to support marketing efforts for KetoAir, an FDA-registered breathalyzer aimed at helping consumers track wellness and metabolic health [4]. Leadership and Governance - RPM's CEO, Michael Mathews, has been appointed to Avalon's board of directors as part of the acquisition deal [6]. - Avalon is also pursuing a separate merger with YOOV Group Holdings Limited, with an S-4 registration statement filed with the SEC [6]. Market Reaction - Following the announcement, ALBT shares were trading 13.97% lower at $1.17 in premarket trading [6].

FREEHOLD, N.J., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of precision diagnostic consumer products, today announced a series of Q3 2025 advancements for KetoAir™, including expanded deployment, the launch of a first-responder metabolic health program, and entry into an international market. Key Highlights Launched Holistic Health Reset Program with First Responders in NevadaIn August 2025, Avalon, together with Saga Health and Specialty ...

Revenue and Income - For the three months ended September 30, 2025, real property rental revenue was $350,099, an increase of $4,940 or 1.4% compared to $345,159 for the same period in 2024[264]. - For the nine months ended September 30, 2025, real property rental revenue was $1,050,305, an increase of $62,671 or 6.3% compared to $987,634 for the same period in 2024[264]. - Real property operating income for the three months ended September 30, 2025 was $115,733, an increase of $16,102 or 16.2% compared to $99,631 for the same period in 2024[268]. - Real property operating income for the nine months ended September 30, 2025 was $284,472, an increase of $90,980 or 47.0% compared to $193,492 for the same period in 2024[268]. - For the nine months ended September 30, 2025, the company reported income from Lab Services MSO of $392,677, which included its share of net income and amortization of identifiable intangible assets[270]. Expenses and Losses - The company incurred a working capital deficit of approximately $11,515,000 at September 30, 2025, with recurring net losses of approximately $16,195,000 for the nine months ended September 30, 2025[253]. - The company generated negative cash flow from operating activities of approximately $4,389,000 for the nine months ended September 30, 2025[253]. - For the three months ended September 30, 2025, advertising and marketing expenses increased by $104,287, or 72.1%, compared to the same period in 2024, while for the nine months, the increase was $390,329, or 154.7%[273]. - Professional fees for the three months ended September 30, 2025, rose by $945,150, or 311.6%, primarily due to increased consulting and legal service fees related to a potential merger with YOOV Group[275]. - Compensation and related benefits decreased by $112,976, or 32.9%, for the three months ended September 30, 2025, and by $159,333, or 15.1%, for the nine months, mainly due to reduced compensation for the executive officer[275]. - Miscellaneous taxes increased by $31,600, or 263.3%, for the three months ended September 30, 2025, primarily due to an increase in Delaware state franchise tax[275]. - Loss from operations for the three months ended September 30, 2025, was $76,193, a decrease of $1,193,768, or 94.0%, compared to the same period in 2024[277]. - Net loss for the three months ended September 30, 2025, was $254,268, a decrease of $1,424,932, or 84.9%, compared to the same period in 2024[282]. - The net loss attributable to common shareholders for the nine months ended September 30, 2025, was $16,032,504, or $6.10 per share, representing an increase of $10,853,765, or 209.6%[284]. - Comprehensive loss for the three months ended September 30, 2025, was $253,997, compared to $1,676,157 for the same period in 2024[286]. Cash Flow and Capital - As of September 30, 2025, the company's cash balance was approximately $334,000, a decrease from $2,856,000 on December 31, 2024[288]. - The working capital deficit increased by $868,585 to $11,514,642 at September 30, 2025, compared to $10,646,057 at December 31, 2024, primarily due to a decrease in cash and increases in accrued liabilities[290]. - Net cash used in operating activities for the nine months ended September 30, 2025, was $4,388,557, reflecting a consolidated net loss of approximately $16,195,000[292]. - Net cash flow provided by investing activities was $752,635 for the nine months ended September 30, 2025, compared to a net cash flow used of $100,000 for the same period in 2024[295]. - Net cash flow provided by financing activities was $1,112,871 for the nine months ended September 30, 2025, down from $4,726,942 in the same period of 2024[296]. - The company expects cash used in operating activities to increase in the next 12 months due to new product development and increased marketing efforts[294]. - The company estimates that its available cash will be insufficient to meet its cash requirements under current operating expectations, necessitating significant additional capital[298]. Operational Changes and Future Outlook - The company suspended all research and development efforts related to cellular therapy to focus on product commercialization[251]. - The KetoAir breathalyzer device is registered with the U.S. FDA as a Class I medical device and is marketed for the diabetes and obesity markets[244][247]. - The company sold its 40% equity interest in Lab Services MSO on February 26, 2025, resulting in no income from this investment for the three months ended September 30, 2025[269]. - The company faces substantial doubt about its ability to continue as a going concern, dependent on raising additional capital and generating sufficient revenues[287]. - The unrealized foreign currency translation gain for the nine months ended September 30, 2025, was approximately $700, compared to $2,800 for the same period in 2024[299]. - The company has ceased all operations in China since 2022, limiting exposure to foreign currency exchange rate fluctuations[299]. - The increase in working capital requirements is attributed to financing current business operations and capital for acquisitions[301].

Core Viewpoint - Avalon GloboCare Corp. is launching the KetoAir™ breathalyzer device in the UK, expanding its market presence following its U.S. launch, targeting individuals on ketogenic diets for health management [1][3]. Product Overview - KetoAir™ is a handheld breathalyzer that measures breath acetone concentration (BrAce), indicating fat metabolism and ketosis, and is registered as a Class I medical device with the U.S. FDA [2][4]. - The device is designed for users pursuing ketogenic diets for weight loss, athletic performance, or therapeutic purposes, utilizing advanced nano-sensor technology for real-time metabolic insights [2][3]. Market Strategy - The launch in the UK is seen as a strategic move to capitalize on the growing adoption of ketogenic and low-carb diets, positioning KetoAir™ as a tool to help individuals achieve their health and wellness goals [3]. - The product will be available for purchase starting September 1, 2025, through the dedicated website [1][3]. Company Background - Avalon GloboCare Corp. focuses on developing precision diagnostic consumer products and advancing intellectual property in cellular therapy, with plans to explore additional diagnostic uses for the breathalyzer technology [4].

Revenue and Income - Real property rental revenue for Q2 2025 was $350,406, an increase of $22,519 or 6.9% compared to Q2 2024[263] - Real property operating income for Q2 2025 was $99,329, an increase of $56,930 or 134.3% compared to Q2 2024[267] - For the six months ended June 30, 2025, real property rental revenue was $700,206, up $57,731 or 9.0% from the same period in 2024[263] Expenses and Losses - Real property operating expenses for Q2 2025 decreased to $251,077, down $34,411 or 12.1% from Q2 2024[265] - Loss from operations for the three months ended June 30, 2025, amounted to $3,887,987, representing an increase of $2,383,624, or 158.4%, compared to the same period in 2024[274] - Other expense, net, totaled $9,570,611 for the three months ended June 30, 2025, representing an increase of $8,942,948, or 1,424.8%, primarily due to increased third-party interest expense and loss on extinguishment of debt[276] - Net loss for the three months ended June 30, 2025, was $13,458,598, an increase of $11,326,572, or 531.3%, compared to the same period in 2024[279] - The net loss attributable to common shareholders for the three months ended June 30, 2025, was $13,458,598, or $6.22 per share, compared to $2,132,026, or $2.85 per share, for the same period in 2024[280] - Comprehensive loss for the three months ended June 30, 2025, was $13,458,494, compared to $2,129,320 for the same period in 2024[283] Cash Flow and Working Capital - The company incurred a working capital deficit of approximately $14,132,000 as of June 30, 2025[252] - The company generated negative cash flow from operating activities of approximately $3,028,000 for the six months ended June 30, 2025[252] - As of June 30, 2025, the company's cash balance was approximately $201,532, a decrease of 92.9% from $2,856,309 on December 31, 2024[286] - The working capital deficit increased by $3,486,262 to $14,132,319 at June 30, 2025, primarily due to a decrease in cash and increases in accrued liabilities[286] - Net cash used in operating activities for the six months ended June 30, 2025 was $3,027,822, reflecting a consolidated net loss of approximately $15,941,000[289] - The company reported a net cash flow provided by financing activities of $277,636 for the six months ended June 30, 2025, a significant decrease from $2,010,577 in the same period of 2024[292] - The company expects cash used in operating activities to increase in the next 12 months due to rising operational costs and working capital requirements[291] Assets and Liabilities - The total current assets decreased by 71.2% from $3,236,498 on December 31, 2024 to $933,088 on June 30, 2025[286] - The total current liabilities increased by 8.5% from $13,882,555 on December 31, 2024 to $15,065,407 on June 30, 2025[286] Business Operations and Strategy - The company has suspended all research and development efforts related to cellular therapy to focus on product commercialization[250] - The company plans to target the diabetes and obesity markets with the KetoAir breathalyzer device[246] - The KetoAir device is registered as a Class I medical device with the U.S. FDA and is paired with an "AI Nutritionist" software program[248] - The company has ceased all operations in China since 2022, limiting future revenue generation from that market[296] - The company will need to raise significant additional capital to fund operations and provide working capital, with no assurance that financing will be available on acceptable terms[295] Financial Viability - The company has a limited operating history and its continued growth is dependent on generating rental revenue and obtaining additional financing, raising substantial doubt about its ability to continue as a going concern[285]

Core Viewpoint - Avalon GloboCare Corp. has announced a wholesale distribution agreement with Saga Health Corporation for the KetoAir™ breathalyzer device, aimed at first responders as part of Saga's Holistic Health Reset Program [1][3]. Company Overview - Avalon GloboCare Corp. (NASDAQ: ALBT) specializes in precision diagnostic consumer products and cellular therapy intellectual property [5]. - The company is currently marketing the KetoAir™ breathalyzer, which is registered as a Class I medical device with the U.S. FDA [5]. - Avalon also focuses on advancing its intellectual property portfolio through existing patent applications and operates commercial real estate [5]. Product Details - The KetoAir™ breathalyzer is designed for ketogenic health management, measuring breath acetone concentration (BrAce) to indicate fat metabolism and ketosis [2]. - It is intended for users on ketogenic diets for weight loss, athletic performance, or therapeutic purposes, utilizing nano-sensor technology for real-time insights [2]. - The device is compatible with both Apple and Android devices and is available on the Apple App Store and Google Play Store [2]. Partnership Significance - The agreement with Saga Health is seen as a milestone for accelerating the commercial expansion of the KetoAir™ device [3]. - The collaboration aims to meet the growing demand for personalized, real-time monitoring of BrAce among those pursuing ketogenic lifestyles [3]. - Saga Health's Holistic Health Reset Program provides personalized nutritional guidance and tools like the KetoAir™ breathalyzer to improve participants' health [6].